evipedia.ai
← Back

Centrophenoxine for Health & Longevity

Evidence Review created on 09/28/2026 using AI4L / Opus 5.5

Also known as: Meclofenoxate, Meclophenoxate, Centrophenoxin, Clofenoxine, CPH, Meclofenoxate Hydrochloride, dimethylaminoethyl p-chlorophenoxyacetate, ANP 235, Lucidril, Helfergin, Cerutil

Motivation

Centrophenoxine, also called meclofenoxate, is a synthetic compound built from two smaller molecules: a close chemical relative of the nutrient choline, which the brain uses to make a key memory messenger, and a plant growth hormone thought to help carry it into the brain. It is a prescription medicine in some countries and is sold online as a brain-health supplement elsewhere. Interest in it centers on memory and on the idea that it might clear the yellow-brown age pigment that builds up inside aging nerve cells.

Developed in France in the 1950s, it was studied for decades in older adults with memory complaints. Its standing among longevity-minded people traces largely to laboratory animal research from the 1970s on brain aging and life span, and it has resurfaced in modern brain-supplement blends.

This review examines the human and animal evidence on centrophenoxine for memory, brain aging and life span, its known and suspected risks, and how it has been dosed and monitored, to show where the evidence stands for health-focused adults.

Benefits - Risks - Protocol - Conclusion

The sources below give a high-level overview of centrophenoxine’s history, mechanisms, evidence and safety.

Only three sources qualified. No content on centrophenoxine was found from Rhonda Patrick, Peter Attia, Andrew Huberman or Chris Kresser, and Life Extension Magazine mentions it only in passing, so the list was not padded with marginally relevant material.

Grokipedia

Meclofenoxate

An AI-generated encyclopedia entry summarizing approved uses by country, typical dosing, side effects, the anti-doping ban and recent Parkinson’s disease repurposing work; useful orientation, but claims need checking against primary sources.

Examine

Centrophenoxine

Examine’s supplement page, written by Kamal Patel, describes centrophenoxine as a better-absorbed DMAE source and lists 250 mg doses taken one to three times daily, with higher short-term doses for lipofuscin.

ConsumerLab

No dedicated ConsumerLab article on centrophenoxine exists; ConsumerLab rarely covers prescription medications, which centrophenoxine is in several countries. It appears only in a 2022 clinical update and a members-only memory answer.

Systematic Reviews

The reviews below are the only systematic reviews or meta-analyses (pooled analyses of several trials) on PubMed that include centrophenoxine trials; each covers a broader drug class or condition.

No systematic review or meta-analysis addresses centrophenoxine’s safety, its effect on memory in healthy aging, or life span; the principal risks and the central longevity claim are therefore unrepresented in this section.

Mechanism of Action

Centrophenoxine is an ester (a chemically bonded pair of molecules) of DMAE and pCPA. After oral intake, esterases (enzymes that split such bonds) in blood and liver break it down so quickly that the intact compound is not detectable in blood (Zou et al., 2008).

  • Acetylcholine support: DMAE resembles choline, the building block of acetylcholine (the chemical messenger for memory and attention); pCPA may help DMAE reach the brain. Whether DMAE actually raises brain acetylcholine is disputed; it may instead compete with choline for brain entry.
  • Membrane hypothesis of aging: Imre Zs-Nagy proposed that DMAE enters cell membranes and neutralizes hydroxyl radicals (highly reactive oxygen fragments), rehydrating aged cells (Nagy & Floyd, 1984).
  • Lipofuscin removal: Early rodent studies reported less age pigment in neurons (Nandy, 1978), but independent groups found no reduction (Katz & Robison, 1983).
  • Newer targets: Model studies link it to binding the sigma-1 receptor (a cell-stress protein) and to less alpha-synuclein clumping (the protein that aggregates in Parkinson’s disease) (Zhang et al., 2025; Parui et al., 2023).

Pharmacology: The parent compound’s half-life is very short (it is undetectable in blood); pCPA is the measured circulating metabolite, tracked over 24 hours after a 200 mg dose, and human half-lives of pCPA and DMAE are poorly characterized. Selectivity (how narrowly it acts on one target) is low. DMAE reaches the brain. Metabolism is by esterase hydrolysis; no CYP (cytochrome P450, the liver’s main drug-processing enzymes) pathway is established, and pCPA is excreted in urine.

Historical Context & Evolution

Centrophenoxine was synthesized in France in the late 1950s by joining DMAE to pCPA, a synthetic auxin (plant growth hormone), on the theory that the carrier would help DMAE reach the brain. It was marketed as Lucidril and similar brands for “cerebral insufficiency” (declining mental function attributed to poor brain blood flow), clouded consciousness and dizziness after head injury, and delirium tremens (severe alcohol withdrawal), and in China for alcohol poisoning, newborn oxygen deprivation and childhood bedwetting (Zou et al., 2008).

Interest for health optimization grew from rodent work in which it reduced neuronal lipofuscin and improved maze learning (Nandy, 1978), and from a 1973 study in which treated male mice lived longer (Hochschild, 1973). In the 1980s Imre Zs-Nagy built the membrane hypothesis of aging partly around it, and popular “smart drug” books spread its use.

The picture then became mixed. Independent rodent studies did not reproduce the lipofuscin reduction (Dowson, 1985), human trials stayed small, and a trial of a related DMAE compound in early Alzheimer’s disease showed no cognitive effect (Dubois et al., 2012). These findings leave the original observations unreplicated rather than refuted. More recently, a drug-screening study revived interest in Parkinson’s disease models (Zhang et al., 2025), while a 2022 analysis found the unapproved drug sold as US supplements (Cohen et al., 2022).

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human outcomes rest on small randomized or non-randomized trials from 1967–2003, each either a single unreplicated trial or, for memory, trials with conflicting results.

Medium 🟩 🟩

Fewer Urinary Symptoms After Stroke ⭕️ Not Central to Health & Longevity

In one small randomized trial of stroke survivors, pooled in a Cochrane review, fewer patients given meclofenoxate reported urinary symptoms than controls (Thomas et al., 2008). The mechanism is unclear; better brain control of the bladder has been proposed. Trial quality was uncertain, and the reviewers judged the overall evidence insufficient to guide care. This bears on recovery after stroke, not on healthy aging or life span.

Magnitude: 9 of 40 treated versus 27 of 40 control patients had urinary symptoms (risk ratio 0.33, 95% confidence interval 0.18–0.62; risk ratio = chance relative to controls, confidence interval = plausible range of the true effect).

Low 🟩

Memory in Older Adults ⚠️ Conflicted

Meclofenoxate improved long-term memory storage in fit older adults (Marcer & Hopkins, 1977) and helped more moderate-dementia patients than placebo over 8 weeks (Pék et al., 1989). A shorter 3-week trial in 28 memory-impaired patients found no effect (Oliver & Restell, 1967). Net: inconsistent, possibly duration-dependent evidence.

Magnitude: 48% of treated versus 28% of placebo patients with moderate dementia improved on memory measures after 8 weeks at 2 g/day (Pék et al., 1989); fit older adults improved on 1 of 6 memory measures (delayed free recall), per the appraisal by the Alzheimer’s Drug Discovery Foundation, a nonprofit with no revenue from the compound, which judges the dementia data inconclusive.

Aerobic Capacity and Fasting Glucose

In a 12-month study, 10 adults (mean age 64) taking 3 g/day showed rising VO2max (peak oxygen use during exercise) and falling fasting glucose versus an untreated, non-randomized comparison group (Schmid & Schlick, 1979). Small and unreplicated.

Magnitude: VO2max rose and fasting glucose fell significantly at 3 g/day over 12 months; the available report gives no outcome figure.

Post-Traumatic Dizziness After Head Injury ⭕️ Not Central to Health & Longevity

A 1968 controlled trial, in which neither patients nor doctors knew who received the drug, tested meclofenoxate for dizziness after head injury (Ito et al., 1968). Its results lack a published abstract, and other reports are uncontrolled case series. This bears on brain-injury recovery, not healthy aging.

Magnitude: Not quantified in available studies. The only controlled trial was published without an abstract, no secondary source reports its outcome figures, and the remaining reports are uncontrolled case series.

Mental Fatigue in Asthenic Conditions ⭕️ Not Central to Health & Longevity

Meclofenoxate is prescribed in some countries for asthenic conditions (persistent mental fatigue and exhaustion) (Bakhtogarimov et al., 2022). A 1983 double-blind trial compared it with placebo in such neurasthenic syndromes (Pieschl et al., 1983), but its results lack a published abstract. This bears on fatigue disorders, not healthy aging.

Magnitude: Not quantified in available studies. The only placebo-controlled trial was published without an abstract, no secondary source reports its outcome figures, and no systematic review has pooled this use.

Speculative 🟨

Longer Life Span in Mice

Male mice given centrophenoxine in drinking water from middle age lived longer than controls, mean survival from treatment start about 27% longer (Hochschild, 1973). Animal data only; no published mammalian replication.

Lipofuscin Clearance in Neurons ⚠️ Conflicted

Early mouse work reported less neuronal lipofuscin and better learning (Nandy, 1978); later independent rat studies found none (Katz & Robison, 1983), possibly from species or measurement differences. Animal data only. Net: contradictory, unresolved evidence.

Neuroprotection in Parkinson’s and Stroke Models

Meclofenoxate protected dopamine neurons in mouse Parkinson’s models and improved memory after reduced brain blood flow in rats (Zhang et al., 2025; Liao et al., 2004). Animal data only.

Cellular Rehydration

Dementia patients on 2 g/day gained 2.2–2.5% intracellular water, read as reversing age-related cell dehydration (Fülöp et al., 1990). Unvalidated biomarker with no shown clinical link.

Benefit-Modifying Factors

  • Genetic polymorphisms: No gene-response studies exist. Variants in PEMT (an enzyme that makes choline in the liver) or CHDH (an enzyme that breaks choline down) alter choline status and could plausibly change response; APOE4 (a gene variant raising Alzheimer’s risk) carriers are untested.
  • Baseline biomarker levels: Low dietary choline or low plasma choline could plausibly increase responsiveness, and normal baseline cognitive scores leave less room to improve; no study has stratified results by these measures.
  • Sex: The mouse life-span study used only males (Hochschild, 1973), and brain gene effects in killifish were stronger in females (Bakhtogarimov et al., 2022); human trials reported no sex-specific results.
  • Pre-existing conditions: Most positive human signals came from people with dementia, stroke or brain injury; healthy adults with normal memory and good blood flow to the brain may gain little.
  • Age: Trial participants averaged 64–77 years, and animal benefits appeared when treatment began in middle or old age; adults at the older end of the range are best represented, younger ones least.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse events come from small trials of centrophenoxine or of DMAE alone, and none has been replicated in trials with systematic adverse-event reporting.

Medium 🟥 🟥

No risk reaches Medium: no controlled trial of centrophenoxine itself reports adverse-event rates, and controlled adverse-event data exist only for DMAE given alone.

Low 🟥

Overstimulation, Insomnia, Headache and Dizziness

Mild stimulant effects, headache and dizziness are most often described, per the Alzheimer’s Drug Discovery Foundation appraisal, a nonprofit earning nothing from the compound. Restlessness and insomnia also occur, mainly at higher or late-day doses. At 3 g/day, 5 of 10 participants noted mild jitteriness (Schmid & Schlick, 1979).

Magnitude: Jitteriness in 5 of 10 participants at 3 g/day over 12 months; rates at common 250–1,000 mg/day doses are not reported.

Gastrointestinal Discomfort

Nausea and short-lived stomach pain are reported. In the same year-long study, 4 of 10 participants had mild gastric pain resolving within about 20 minutes (Schmid & Schlick, 1979). Severity was mild; controlled frequency data are lacking.

Magnitude: Mild gastric pain in 4 of 10 participants at 3 g/day.

Drowsiness, Confusion and Raised Blood Pressure

In a placebo-controlled trial of DMAE alone in moderately severe to severe Alzheimer’s disease, 6 of 13 treated patients withdrew within 5 weeks for drowsiness, increased confusion and mild blood-pressure elevation (Fisman et al., 1981). Relevance to centrophenoxine, which releases DMAE, is indirect.

Magnitude: 6 of 13 (46%) DMAE-treated patients withdrew because of these adverse events.

Mood Changes

Of 38 patients on high-dose deanol (DMAE), 5 became depressed and 3 hypomanic (abnormally elevated, driven mood); 7 of these 8 had prior mood symptoms (Casey, 1979). No comparable data exist for centrophenoxine itself.

Magnitude: 8 of 38 (21%) patients on high-dose DMAE developed mood changes.

Serious Cardiac Events and Seizure

In a 242-patient trial of V0191, a DMAE salt, in early Alzheimer’s disease (Dubois et al., 2012), the nonprofit Alzheimer’s Drug Discovery Foundation, which earns nothing from the compound, reports cardiac failure with death, cardiac arrest and a seizure, relatedness not excluded. These are isolated events with a related compound.

Magnitude: 3 serious adverse events in a trial of 242 patients randomized about 1:1; causality undetermined.

Speculative 🟨

Birth Defects

DMAE caused neural tube defects (malformed brain and spinal cord) and facial underdevelopment in cultured mouse embryos by blocking choline uptake (Fisher et al., 2001). Animal data only; no human pregnancy data.

Unfavorable Brain Gene Expression

In aging killifish, lifelong meclofenoxate restored neuronal genes but not rising inflammatory genes, and increased transposon (mobile DNA) activity (Bakhtogarimov et al., 2022). Animal data only; significance unclear.

Risk-Modifying Factors

  • Genetic polymorphisms: No studies exist. Variants in BCHE (butyrylcholinesterase, an enzyme that splits choline esters) could plausibly alter breakdown speed, and PEMT or CHDH variants alter choline handling; none has been tested.
  • Baseline blood pressure: DMAE raised blood pressure in one trial (Fisman et al., 1981), so people starting with readings at or above 130/80 mmHg carry more risk of reaching harmful levels.
  • Sex: No sex differences in side effects are reported; women who could become pregnant carry the added animal birth-defect signal.
  • Pre-existing conditions: Epilepsy, bipolar or other mood disorders, severe hypertension, heart disease and agitation raise risk; liver or kidney impairment is unstudied, so clearance may be slower.
  • Age: Confusion and drowsiness on DMAE occurred in older adults with severe dementia (Fisman et al., 1981); frail older adults may be more sensitive, while healthy younger adults are underrepresented in safety data.

Key Interactions & Contraindications

  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine): Caution. Combined cholinergic (acetylcholine-boosting) effects with these drugs (which block acetylcholine breakdown) may cause nausea, slowed heart rate or muscle cramps. Mitigation: combined use under physician supervision with pulse tracking.
  • Anticholinergic prescription drugs (oxybutynin, tolterodine, amitriptyline): Monitor. These drugs (which block acetylcholine) have opposing actions that may cancel the intended effect or destabilize bladder and cognitive symptoms. Mitigation: prescriber review of total anticholinergic load.
  • Alkylating chemotherapy (DNA-damaging cancer drugs; cyclophosphamide, chlorambucil): Avoid during treatment. Centrophenoxine increased the cell-killing effect of these drugs up to 7-fold in cultured cancer cells (Sladek, 1977), making toxicity unpredictable. Mitigation: stopping before chemotherapy unless the oncologist agrees.
  • Stimulant medications (methylphenidate, amphetamine, modafinil): Caution. Additive stimulation may cause insomnia, anxiety and raised blood pressure. Mitigation: lowest dose, morning timing only.
  • Anticonvulsants (anti-seizure drugs; valproate, levetiracetam, lamotrigine): Caution. A seizure occurred in a DMAE-salt trial (Dubois et al., 2012), and cholinergic stimulation may lower the seizure threshold of people on these drugs, risking breakthrough seizures. Mitigation: avoidance in epilepsy.
  • Over-the-counter anticholinergics (diphenhydramine, doxylamine): Monitor. These sleep aids and antihistamines oppose centrophenoxine’s effect and may blunt any cognitive benefit. Mitigation: non-anticholinergic alternatives.
  • Over-the-counter stimulants (pseudoephedrine, caffeine tablets): Caution. Additive effects on alertness, heart rate and blood pressure. Mitigation: caffeine limited to about 200 mg/day and no decongestants during use.
  • Additive cholinergic supplements (alpha-GPC, citicoline, DMAE, huperzine A): Caution. Choline donors such as alpha-GPC (alpha-glycerylphosphorylcholine, a choline source) and huperzine A (a plant compound that blocks acetylcholine breakdown) add to cholinergic effects, raising headache, nausea and overstimulation risk. Mitigation: introducing one at a time.
  • Stimulant supplements (yohimbine, synephrine): Caution. Additive stimulation and blood-pressure elevation. Mitigation: no combined use.
  • Competitive sport drug testing: Absolute contraindication in competition. Meclofenoxate is a prohibited specified stimulant under the World Anti-Doping Agency (WADA) list; use risks sanctions. Mitigation: athletes typically stop well before competition.

Populations who should avoid Centrophenoxine:

  • Pregnant or breastfeeding women and those trying to conceive
  • People with epilepsy or any unprovoked seizure within the past 5 years
  • People with uncontrolled hypertension (resting blood pressure ≥160/100 mmHg)
  • People with bipolar disorder or any past episode of mania or hypomania
  • People with psychosis or marked agitation
  • People receiving alkylating chemotherapy
  • Children and adolescents under 18 years
  • Athletes subject to in-competition anti-doping testing
  • People with severe liver impairment (Child-Pugh Class C, the most advanced liver-failure category) or severe kidney impairment (eGFR, estimated glomerular filtration rate, below 30 mL/min/1.73 m²)

Risk Mitigation Strategies

  • Low start, slow titration: Protocols typically begin at 250 mg once daily and increase by 250 mg every 1–2 weeks to 500–1,000 mg/day only if tolerated, limiting jitteriness, headache and insomnia.
  • Morning and midday dosing: Protocols place the last dose before 2 p.m. to prevent insomnia from stimulant-like effects.
  • Dosing with food: Taking doses with meals reduces nausea and stomach pain.
  • Blood pressure tracking: Home blood pressure is typically checked weekly for the first 4 weeks, then monthly, with use stopped if systolic pressure rises 10 mmHg or more above baseline or readings exceed 140/90 mmHg, preventing sustained DMAE-related elevation.
  • Mood tracking: Weekly mood ratings during the first 8 weeks, with use stopped at any sign of depression or elevated mood, limit the DMAE-linked mood-change risk.
  • Pregnancy exclusion: Reliable contraception during use and stopping before attempting conception avoid the animal birth-defect risk.
  • Verified products: Products with a batch-specific certificate of analysis showing 95–105% of labeled content prevent accidental overdosing and its side effects.
  • One cholinergic at a time: Leaving out other choline donors or huperzine A during the first 4 weeks prevents headache and cholinergic excess.
  • Pause for chemotherapy: Stopping at least 1 week before alkylating chemotherapy avoids unpredictable toxicity potentiation.

Therapeutic Protocol

  • Common supplement protocol: 250 mg taken one to three times daily (250–750 mg/day), matching Examine’s summary and US supplement labels, which provide 237–752 mg/day (Cohen et al., 2022).
  • Clinical trial doses: 1,200 mg/day in healthy older adults (Marcer & Hopkins, 1977), 2,000 mg/day in dementia (Pék et al., 1989), 3,000 mg/day for 12 months (Schmid & Schlick, 1979); side effects rose with dose.
  • High-dose “clearing” course: 1980s longevity writers Durk Pearson and Sandy Shaw (“Life Extension”) and Ward Dean and John Morgenthaler (“Smart Drugs & Nutrients”) popularized short high-dose courses (750–1,500 mg/day) aimed at lipofuscin, followed by lower maintenance.
  • Alternative approach: Many practitioners use direct choline donors (citicoline, alpha-GPC) instead, which have more modern human trials; centrophenoxine advocates cite its additional membrane and pigment rationale.
  • Time of day: Morning and early afternoon, because stimulant-like effects can delay sleep onset.
  • Half-life: The parent compound is split so fast it is undetectable in blood; metabolite half-lives are poorly characterized, and effects are considered short-lived.
  • Single versus split dosing: Split doses (two to three times daily) are standard because of the short action; single doses above 500 mg increase jitteriness.
  • Genetic polymorphisms: No variant (e.g., PEMT, CHDH, APOE4) has an established dose adjustment.
  • Sex: No sex-specific dosing exists; protocols pair use in women who could become pregnant with reliable contraception.
  • Age: Older adults typically start at 250 mg/day; trials in people averaging 64–77 years used 1,200–3,000 mg/day.
  • Baseline biomarkers: Protocols typically require blood pressure below 130/80 mmHg, normal liver enzymes and adequate dietary choline (425 mg/day for women, 550 mg/day for men) before starting.
  • Pre-existing conditions: Studied populations included cerebrovascular disease (disease of the brain’s blood vessels, including stroke) and dementia under medical care; epilepsy and bipolar disorder are exclusions.

Discontinuation & Cycling

  • Short-term, not lifelong: Human studies lasted 3 weeks to 12 months; no data support indefinite use, so courses are typically time-limited with reassessment.
  • Withdrawal effects: No withdrawal or rebound effects have been reported after stopping.
  • Tapering: No tapering protocol has been studied or appears necessary; higher doses (1,000 mg/day or more) are sometimes stepped down over 1 week for comfort.
  • Cycling: Users of nootropics (cognitive-enhancing supplements) commonly cycle 8–12 weeks on and 2–4 weeks off to limit tolerance and side effects; this practice has no supporting trial data.
  • Stop rule: Protocols typically end use if no measurable cognitive or subjective change appears after 12 weeks, or at any sign of mood change, sustained blood-pressure rise or pregnancy.

Sourcing and Quality

  • Regulatory gray zone: In the US centrophenoxine is an unapproved drug sold as a “dietary supplement,” so products escape pharmaceutical-grade oversight (Cohen et al., 2022).
  • Label accuracy: In US testing (Cohen et al., 2022), products held 79–251 mg per serving, and only 1 of 7 matched its label within ±10%, so real intake can differ substantially from the label.
  • Form and stability: Centrophenoxine is sold as the hydrochloride salt, usually 200–300 mg capsules or powder; it breaks down in alkaline water (El-Bardicy et al., 2007), so dry, sealed storage matters.
  • What to look for: A batch-specific certificate of analysis from an independent lab using HPLC (high-performance liquid chromatography, a purity test) showing 98% or higher purity, plus heavy-metal and microbial testing.
  • Pharmaceutical sources: Registered medicines such as Lucidril (Kyowa Yakuhin, Japan; Minapharm, Egypt) are produced under drug-manufacturing standards and are the most consistent source where legally available.
  • Brands: No supplement brand has been independently verified in published testing; ConsumerLab and USP (United States Pharmacopeia) do not certify centrophenoxine products.

Practical Considerations

  • Time to effect: Trials assessed memory after 3–8 weeks; self-reported alertness may appear within days, while any effect on brain aging or life span would not be observable on a personal time scale.
  • Common pitfalls: Evening dosing, stacking several choline donors, trusting label doses, and treating mouse life-span data as proof of human benefit.
  • Regulatory status: Prescription medicine in Japan, China and several European countries; not approved by the FDA (US Food and Drug Administration); prohibited in competition by WADA.
  • Cost and access: Inexpensive and widely sold online, as are its alternatives, so payer cost incentives are not a meaningful source of bias; the practical barrier is product quality, not price.

Interaction with Foundational Habits

  • Sleep: Blunting. Stimulant-like effects can delay sleep onset, and acetylcholine drives REM (rapid eye movement, dreaming) sleep, so evening doses may alter sleep structure. Taking the last dose before 2 p.m. and tracking sleep quality addresses this.
  • Nutrition: Indirect. Choline-rich foods (eggs, liver, fish) supply the same pathway, and small amounts of DMAE occur naturally in fish such as sardines and anchovies. Taking doses with meals reduces gastrointestinal discomfort; very high choline intake alongside may add to headache.
  • Exercise: Possibly potentiating. One small study found higher VO2max after a year at 3 g/day (Schmid & Schlick, 1979), and no data suggest blunted muscle gains. Morning dosing before training is compatible, though stimulant effects may raise exercise heart rate.
  • Stress management: Possibly blunting. Stimulant jitteriness can heighten anxiety, and DMAE has been linked to mood changes in predisposed people; no cortisol data exist. Pairing use with established stress practices and pausing during acute stress limits this.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes safety and a reference point: seated blood pressure and resting heart rate on three separate mornings, a fasting blood panel with liver enzymes (ALT and AST, alanine and aspartate aminotransferase), kidney function (eGFR), fasting glucose and homocysteine (a blood amino acid reflecting B-vitamin and choline status), a pregnancy test where applicable, and a standardized computerized cognitive test taken at a fixed time of day.

Ongoing monitoring follows this cadence: blood pressure weekly for the first 4 weeks and then monthly; repeat labs and cognitive testing at 8–12 weeks; then every 6 months for as long as use continues. Success means a measurable cognitive gain over the personal baseline, stable blood pressure, normal labs and no sleep or mood disturbance.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <120/80 mmHg DMAE raised blood pressure Conventional normal <130/80 mmHg; seated, morning, before dosing
Resting heart rate 50–70 beats/min Detects stimulant or cholinergic effects Conventional range 60–100 beats/min; measure on waking
ALT 10–25 U/L Liver processes the compound ALT = alanine aminotransferase, a liver enzyme; conventional upper limit about 40–55 U/L
AST 10–25 U/L Liver safety AST = aspartate aminotransferase; conventional upper limit about 40 U/L; pair with ALT; avoid hard exercise 48 hours before
eGFR >90 mL/min/1.73 m² Kidneys clear pCPA eGFR = estimated glomerular filtration rate; conventional normal >60
Fasting glucose 75–90 mg/dL One study reported lower fasting glucose Conventional 70–99 mg/dL; 8–12 hour fast; pair with HbA1c (3-month average blood sugar)
Homocysteine 5–8 µmol/L Reflects choline and methylation (chemical tagging of DNA and proteins) status Conventional upper limit about 15 µmol/L; fasting sample
Cognitive test score No established target; track change from own baseline Objective check of benefit Same test, time of day and conditions each round
Pregnancy test Negative Excludes pregnancy hCG (pregnancy hormone) test for women who could become pregnant

Qualitative markers:

  • Sleep onset time and sleep quality
  • Daytime mental alertness and focus
  • Recall of names, lists and recent events
  • Mood stability, irritability or unusual elation
  • Headache frequency, jitteriness and stomach comfort

Emerging Research

  • Registered trial in liver-related brain dysfunction: “Coenzyme Q10 and Meclofenoxate in Hepatic Encephalopathy” (NCT03961087), Zagazig University, 300 participants planned, phase not applicable, status unknown; measures hepatic encephalopathy (brain dysfunction from liver failure) episodes, quality of life and blood ammonia over 6 months. No registered trial studies aging or life span.
  • Parkinson’s disease repurposing: A multi-omics (combined gene-activity data) drug screen identified meclofenoxate, which protected neurons and improved motor function in mice via sigma-1 binding (Zhang et al., 2025); human trials would test whether this strengthens the neuroprotection case.
  • Alpha-synuclein aggregation: Meclofenoxate reduced alpha-synuclein clumping in test-tube experiments (Parui et al., 2023), a mechanism that could support the Parkinson’s findings.
  • Mixed brain-aging signal: In killifish, lifelong treatment restored neuronal genes but raised inflammatory and transposon activity (Bakhtogarimov et al., 2022), a result that could weaken the brain-aging case.
  • Plaque-associated enzyme inhibition: Meclofenoxate inhibited acetylcholine-degrading enzymes linked to Alzheimer’s plaques in brain tissue (Darvesh et al., 2025), suggesting a second cognitive mechanism.
  • Negative precursor trial: A DMAE-salt trial in early Alzheimer’s disease found no cognitive benefit (Dubois et al., 2012), weakening the choline-precursor rationale; a modern centrophenoxine trial would be decisive.
  • Life-span replication gap: The 1973 mouse result (Hochschild, 1973) has not been repeated in genetically diverse mice of both sexes; such a test could confirm or overturn the longevity claim.

Conclusion

Centrophenoxine is an older brain medicine, sold as a supplement in some markets, that splits into a choline-like molecule and a plant-hormone carrier after oral intake. For health-focused adults, its appeal rests on two ideas: modest support for memory in later life, and slower brain aging and longer life suggested by animal studies.

The human evidence is thin. It comes from a handful of small, decades-old studies in older adults, people with dementia and stroke survivors, with some favorable results that were never repeated and others showing no effect. The life-span and age-pigment findings come from animals, and independent laboratories disagree about the pigment results. Some of the most favorable work came from the researcher who built a theory of aging around the compound and developed a successor compound, a potential conflict of interest; the nonprofit foundation appraisal drawn on here earns nothing from its sale.

Reported side effects are mostly mild and more common at higher doses: restlessness, poor sleep, headache, dizziness and digestive discomfort. More serious concerns come mainly from studies of its choline-like component: raised blood pressure, confusion, mood swings, and birth defects in animal embryos. Product quality adds uncertainty, since supplements often contain doses that differ from their labels.

Overall, centrophenoxine is a low-cost compound with a long history and a plausible rationale, but its evidence base is too small and dated to confirm benefits for memory or longevity in healthy adults.

Top - Benefits - Risks - Protocol